News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
31,034 Results
Type
Article (1767)
Company Profile (208)
Press Release (29116)
Multimedia
Podcasts (9)
Webinars (2)
Section
Business (13973)
Career Advice (42)
Deals (2027)
Drug Delivery (5)
Drug Development (4100)
Employer Resources (12)
FDA (686)
Job Trends (950)
News (18791)
Policy (995)
Tag
2027 BioCapital Elite (1)
2027 BioCapital Standard (1)
2027 Biotech Bay Elite (1)
2027 Biotech Bay Standard (1)
2027 Biotech Beach Standard (3)
2027 Genetown Standard (3)
2027 Pharm Country Digital (1)
2027 Pharm Country Premier (1)
Academia (81)
Accelerated approval (10)
ADA (7)
Allergies (12)
Alliances (727)
ALS (21)
Alzheimer's disease (110)
Antibody-drug conjugate (ADC) (54)
Approvals (771)
Artificial intelligence (46)
ASCO (36)
Autoimmune disease (36)
Automation (1)
Bankruptcy (6)
Best Places to Work (900)
BIO (2)
Biologics (1)
Biosimilars (19)
BioSpace Insights (10)
Biotechnology (165)
Bladder cancer (32)
Breast cancer (90)
Cancer (593)
Cardiovascular disease (56)
Career advice (38)
Career pathing (2)
CAR-T (16)
CDC (1)
CDMO (5)
Cell therapy (47)
Cervical cancer (2)
Clinical research (4244)
Collaboration (102)
Commercialization (3)
Compensation (103)
Complete response letters (6)
COVID-19 (131)
CRISPR (9)
C-suite (41)
Cystic fibrosis (8)
Data (936)
Denatured (5)
Depression (10)
Dermatology (18)
Diabetes (80)
Diagnostics (362)
Digital health (2)
Diversity, equity & inclusion (3)
Drug discovery (18)
Drug pricing (6)
Duchenne muscular dystrophy (17)
Earnings (13977)
Editorial (2)
Employer branding (3)
Employer resources (10)
Events (2871)
Executive appointments (21)
Eye disease (1)
FDA (1096)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (1)
Frontotemporal dementia (2)
Funding (69)
Gene editing (12)
Generative AI (5)
Gene therapy (35)
GLP-1 (102)
Government (133)
Grass and pollen (1)
Guidances (174)
Healthcare (894)
Hematology (17)
HIV (6)
Huntington's disease (5)
IgA nephropathy (34)
Immunology and inflammation (25)
Immuno-oncology (13)
Indications (24)
Infectious disease (160)
Inflammatory bowel disease (8)
Inflation Reduction Act (1)
Influenza (9)
Intellectual property (15)
Interviews (4)
IPO (1553)
IRA (2)
Job creations (125)
Job search strategy (34)
JPM (2)
Kidney cancer (11)
Kidney disease (12)
Labor market (11)
Layoffs (34)
Leadership (3)
Legal (96)
Licensing (2)
Liver cancer (5)
Longevity (1)
Lung cancer (100)
Lung diease (1)
Lymphoma (52)
Machine learning (4)
Management (2)
Manufacturing (47)
MASH (25)
Medical device (842)
Medtech (861)
Mergers & acquisitions (507)
Metabolic disorders (160)
mRNA (55)
Multiple sclerosis (15)
Multispecific (1)
NASH (1)
Neurodegenerative disease (28)
Neuropsychiatric disorders (8)
Neuroscience (231)
NextGen: Class of 2026 (355)
Non-profit (99)
Now hiring (4)
Obesity (55)
Opinion (14)
Ovarian cancer (20)
Pain (18)
Pancreatic cancer (23)
Parkinson's disease (35)
Partnered (3)
Patents (28)
Patient recruitment (33)
Patient selection (1)
Peanut (4)
People (736)
Pharmaceutical (12)
Pharmacy benefit managers (4)
Phase 1 (905)
Phase 2 (1685)
Phase 3 (1969)
Pipeline (1684)
Policy (14)
Postmarket research (174)
Preclinical (225)
Press Release (1)
Prostate cancer (21)
Psychedelics (4)
Radiopharmaceuticals (19)
Rare diseases (68)
Real estate (75)
Recruiting (5)
Regulatory (1101)
Reports (7)
Research institute (60)
Resumes & cover letters (2)
Rett syndrome (3)
RNA editing (3)
RSV (14)
Schizophrenia (15)
Series A (10)
Series B (8)
Service/supplier (5)
Sickle cell disease (5)
Special edition (3)
Spinal muscular atrophy (8)
Sponsored (2)
Startups (81)
Stomach cancer (2)
Substance use disorders (1)
Supply chain (4)
Tariffs (2)
The Weekly (4)
Vaccines (100)
Venture capital (11)
Weight loss (45)
Wet AMD (1)
Women's health (14)
Date
Last 7 days (39)
Last 30 days (127)
Last 365 days (2517)
2026 (1862)
2025 (2579)
2024 (2775)
2023 (2684)
2022 (3031)
2021 (2788)
2020 (2367)
2019 (1889)
2018 (1516)
2017 (1382)
2016 (848)
2015 (1230)
2014 (663)
2013 (515)
2012 (556)
2011 (668)
2010 (651)
Location
Africa (33)
Alabama (6)
Arizona (18)
Asia (2198)
Australia (196)
California (1256)
Canada (308)
China (148)
Colorado (54)
Connecticut (61)
Delaware (65)
Europe (5152)
Florida (157)
Georgia (41)
Idaho (1)
Illinois (86)
India (6)
Indiana (76)
Iowa (2)
Japan (62)
Kansas (11)
Kentucky (7)
Louisiana (10)
Maine (18)
Maryland (154)
Massachusetts (872)
Michigan (25)
Minnesota (70)
Missouri (14)
Montana (1)
Nebraska (3)
Nevada (13)
New Hampshire (7)
New Jersey (415)
New York (356)
North Carolina (181)
Northern California (655)
Ohio (26)
Oklahoma (1)
Pennsylvania (230)
Puerto Rico (1)
Rhode Island (3)
South America (47)
South Carolina (2)
Southern California (461)
Tennessee (14)
Texas (172)
United States (4527)
Utah (47)
Virginia (42)
Washington D.C. (6)
Washington State (144)
Wisconsin (10)
31,034 Results for "73".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
ALS
Nura raises $73.8M to target ALS through a unique target
Nura Bio will use the series B financing to carry two neuroprotective drug candidates through early- to mid-stage clinical studies, one targeting ALS and the other for a broader neurological profile.
June 22, 2026
·
4 min read
·
Michael Gibney
Press Releases
CaseBioscience® Joins Team Awarded Up to $7.3 Million by ARPA-H to Advance Ambient Preservation of Cell Therapies
October 2, 2026
·
4 min read
Press Releases
Nura Bio Completes $73.8M Series B Financing and Advances Pipeline of SARM1 Inhibitors
June 22, 2026
·
3 min read
Press Releases
Antengene Publishes Preclinical Research Paper on CD73 Small Molecule Inhibitor ATG-037 Combined with Selinexor in Cancer Gene Therapy
September 14, 2026
·
5 min read
Press Releases
Ride Therapeutics Announces up to US$7.3 Million Investment from the Cystic Fibrosis Foundation to Advance Next-Generation Genetic Medicines
September 10, 2026
·
3 min read
Press Releases
Oligonucleotide CDMO Market Worth $6.73 Billion by 2029, Growing at 21.8% CAGR
June 10, 2026
·
1 min read
Press Releases
Boehringer Ingelheim delivers on late-stage pipeline with two key launches, grows sales by 7.3%* in a successful 2025
March 25, 2026
·
4 min read
BioMidwest
CinRx Pharma Announces Additional $73 Million Financing
CinRx Pharma today announced the closing of a $73 million financing, bringing the total funds raised to $176 million.
May 30, 2024
·
4 min read
Press Releases
Junshi Biosciences Announces Strategic Collaboration with Antengene to Evaluate Combination Therapy with JS207 (PD-1/VEGF BsAb) and ATG-037 (Oral CD73 Inhibitor)
February 25, 2026
·
8 min read
Press Releases
Medicus Pharma Reports Positive Phase 2 SKNJCT-003 Topline Data Observing 73% Clinical Clearance and 40% Histological Clearance (CR) at Day 57 in 200μg Cohort
March 5, 2026
·
11 min read
1 of 3,104
Next
